HRP20201416T1 - Terapeutska sredstva na bazi sintetaze lantionin c-sličan 2 - Google Patents

Terapeutska sredstva na bazi sintetaze lantionin c-sličan 2 Download PDF

Info

Publication number
HRP20201416T1
HRP20201416T1 HRP20201416TT HRP20201416T HRP20201416T1 HR P20201416 T1 HRP20201416 T1 HR P20201416T1 HR P20201416T T HRP20201416T T HR P20201416TT HR P20201416 T HRP20201416 T HR P20201416T HR P20201416 T1 HRP20201416 T1 HR P20201416T1
Authority
HR
Croatia
Prior art keywords
diyl
alkyl
compound
diamine
disease
Prior art date
Application number
HRP20201416TT
Other languages
English (en)
Inventor
Josep Bassaganya-Riera
Adria CARBO BARRIOS
Richard GANDOUR
Julian D. Cooper
Raquel Hontecillas
Original Assignee
Landos Biopharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Landos Biopharma, Inc. filed Critical Landos Biopharma, Inc.
Publication of HRP20201416T1 publication Critical patent/HRP20201416T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/32—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups
    • C07C65/40—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/60—Two oxygen atoms, e.g. succinic anhydride
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Glass Compositions (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)

Claims (15)

1. Spoj, naznačen time, da je predstavljen sljedećom formulom: [image] ili njegova farmaceutski prihvatljiva sol ili njegov ester, u kojoj: Q je piperazin-1,4-diil; 2,5-diazabiciklo[2.2.1]heptan-2,5-diil; 2,5-diazabiciklo[2.2.2]oktan-2,5-diil; 1,4-diazepan-1,4-diil; benzen-1,4-diamin-N1,N4-diil; etan-1,2-diamin-N1,N2-diil; N1,N2-dialkiletan-1,2-diamin-N1,N2-diil; propan-1,3-diamin-N1,N3-diil; N1,N3-dialkilpropan-1,3-diamin-N1,N3-diil; 1,4-diaminoantracen-9,10-dion-1,4-diil; C6-aren-1,4-diamin-N1,N4-diil gdje je aren supstituiran s jednim do četiri supstituenta na pozicijama 2, 3, 5 ili 6 i pritom su supstituenti neovisno odabrani iz skupine koju čine: -C(O)O(C1 do C6)alkil, OH, O(C1 do C6)alkil, (C1 do C6)alkil, CF3, F, Cl i Br; ili supstituirani piperazin-1,4-diil gdje je piperazin supstituiran s jednim do osam supstituenata na pozicijama 2, 3, 5 ili 6 i pritom su supstituenti neovisno odabrani iz skupine koju čine: (C1 do C6)alkil, aril, aril(C1 do C6)alkil, C(O)OH i C(O)O(C1 do C6)alkil; svaki od A1 i A1' je neovisno N ili CR6; svaki od A2 i A2' je neovisno N ili CR7; A3 je NR8; A3' je NR8, O ili S; svaki od A4 i A4' je neovisno N ili CR9; svaki od A5 i A5' je neovisno N ili CR10; svaki od A6 i A6' je neovisno N ili CR11; i ako su prisutni R1, R1', R2, R2', R3, R3', R4, R4', R6, R7, R8, R9, R10 i R11, u svakom pojavljivanju su neovisno odabrani iz skupine koju čine: vodik, alkil, halo, trifluorometil, dialkilamino gdje je svaki alkil isti ili različit, -NH2, alkilamino i arilalkil.
2. Spoj prema patentnom zahtjevu 1, naznačen time, da jedan od A1 i A1' ili oba je/su N.
3. Spoj prema patentnom zahtjevu 2, naznačen time, da jedan od A2 i A2' ili oba je/su CH, A3 je NH, A4 je N, A5 je CH i A6 je CH.
4. Spoj prema patentnom zahtjevu 2, naznačen time, da jedan od A2 i A2' ili oba je/su CH, jedan od A3 i A3' ili oba je/su NH, jedan od A4 i A4' ili oba je/su N, jedan od A5 i A5' ili oba je/su CH, te jedan od A6 i A6' ili oba je/su CH.
5. Spoj prema bilo kojem od patentnih zahtjeva 1 do 4, naznačen time, da Q je piperazin-1,4-diil; 2,5-diazabiciklo[2.2.1]heptan-2,5-diil; 2,5-diazabiciklo[2.2.2]oktan-2,5-diil; 1,4-diazepan-1,4-diil; N1,N2-dialkiletan-1,2-diamin-N1,N2-diil; N1,N3-dialkilpropan-1,3-diamin-N1,N3-diil; 1,4-diaminoantracen-9,10-dion-1,4-diil; C6-aren-1,4-diamin-N1,N4-diil gdje je aren supstituiran s jednim do četiri supstituenta na pozicijama 2, 3, 5 ili 6 i pritom je svaki supstituent neovisno odabran iz skupine koju čine: -C(O)O(C1 do C6)alkil, OH, O(C1 do C6)alkil, (C1 do C6)alkil, CF3, F, Cl i Br; ili supstituirani piperazin-1,4-diil gdje je piperazin supstituiran s jednim do osam supstituenata na pozicijama 2, 3, 5 ili 6 i pritom je svaki supstituent neovisno odabran iz skupine koju čine: (C1 do C6)alkil, aril, aril(C1 do C6)alkil, C(O)OH i C(O)O(C1 do C6)alkil.
6. Spoj prema patentnom zahtjevu 1, naznačen time, da ako su prisutni R1, R1', R2, R2', R3, R3', R4, R4', R6, R7, R8, R9, R10 i R11, u svakom pojavljivanju su neovisno odabrani iz skupine koju čine: vodik, alkil, halo i trifluorometil.
7. Spoj prema patentnom zahtjevu 1, naznačen time, da spoj ima sljedeću strukturu: [image] [image] ; [image] [image] [image] ili njegove soli.
8. Spoj prema patentnom zahtjevu 1, naznačen time, da spoj ima sljedeću strukturu: [image] ili njegove soli.
9. Spoj prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da se upotrebljava u postupku liječenja zarazne bolesti, autoimune bolesti, dijabetesa ili kronične upalne bolesti.
10. Spoj za uporabu prema patentnom zahtjevu 9, naznačen time, da se upotrebljava u postupku liječenja zarazne bolesti, gdje zarazna bolest obuhvaća virusnu bolest, opcionalno gdje virusna bolest obuhvaća zarazu gripom.
11. Spoj za uporabu prema patentnom zahtjevu 9, naznačen time, da se upotrebljava u postupku liječenja autoimune bolesti, gdje autoimuna bolest obuhvaća autoimunu upalnu bolest, te pritom autoimuna upalna bolest obuhvaća upalnu bolest crijeva.
12. Spoj za uporabu prema patentnom zahtjevu 11, naznačen time, da se kod autoimune upalne bolesti radi o ulcerativnom kolitisu.
13. Spoj za uporabu prema patentnom zahtjevu 11, naznačen time, da se kod autoimune upalne bolesti radi o Crohnovoj bolesti.
14. Spoj za uporabu prema patentnom zahtjevu 9, naznačen time, da se upotrebljava u postupku liječenja dijabetesa, gdje se kod dijabetesa radi o dijabetesu tipa 1 ili dijabetesu tipa 2.
15. Spoj za uporabu prema patentnom zahtjevu 9, naznačen time, da se upotrebljava u postupku liječenja kronične upalne bolesti, gdje kronična upalna bolest obuhvaća metabolički sindrom.
HRP20201416TT 2014-10-24 2020-09-04 Terapeutska sredstva na bazi sintetaze lantionin c-sličan 2 HRP20201416T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462068322P 2014-10-24 2014-10-24
US201562101164P 2015-01-08 2015-01-08
PCT/US2015/021417 WO2016064445A1 (en) 2014-10-24 2015-03-19 Lanthionine synthetase c-like 2-based therapeutics
EP15714352.0A EP3209655B1 (en) 2014-10-24 2015-03-19 Lanthionine synthetase c-like 2-based therapeutics

Publications (1)

Publication Number Publication Date
HRP20201416T1 true HRP20201416T1 (hr) 2020-12-11

Family

ID=52811239

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20201416TT HRP20201416T1 (hr) 2014-10-24 2020-09-04 Terapeutska sredstva na bazi sintetaze lantionin c-sličan 2

Country Status (21)

Country Link
US (9) US9556146B2 (hr)
EP (2) EP3757099B1 (hr)
JP (3) JP6499306B2 (hr)
KR (3) KR20200087273A (hr)
CN (2) CN111592508A (hr)
AU (3) AU2015337091B2 (hr)
BR (1) BR112017008416B1 (hr)
CA (1) CA2965472C (hr)
DK (1) DK3209655T3 (hr)
ES (1) ES2822987T3 (hr)
HR (1) HRP20201416T1 (hr)
HU (1) HUE051299T2 (hr)
IL (2) IL252630B (hr)
LT (1) LT3209655T (hr)
NZ (1) NZ732213A (hr)
PL (1) PL3209655T3 (hr)
PT (1) PT3209655T (hr)
RS (1) RS61013B1 (hr)
RU (3) RU2688677C2 (hr)
SI (1) SI3209655T1 (hr)
WO (1) WO2016064445A1 (hr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3209655T3 (pl) * 2014-10-24 2020-12-28 Landos Biopharma, Inc. Leczenie oparte na białku 2 podobnym do syntetazy lantioniny C
WO2019050890A1 (en) 2017-09-05 2019-03-14 President And Fellows Of Harvard College METHODS AND COMPOSITIONS FOR THE TREATMENT OF TUBERCULOSIS
WO2019099426A1 (en) * 2017-11-17 2019-05-23 Icahn School Of Medicine At Mount Sinai Influenza virus inhibitor targeting nucleoprotein
EA202091325A1 (ru) 2017-11-30 2020-08-28 Лэндос Байофарма, Инк. Способы лечения с помощью лигандов лантионин c-подобного белка 2 и подготовленных с их помощью клеток
TW202039481A (zh) 2018-12-21 2020-11-01 美商西建公司 Ripk2之噻吩并吡啶抑制劑
JP7430852B2 (ja) * 2019-12-20 2024-02-14 エヌイミューン バイオファーマ インコーポレイテッド ランチオニンｃ様タンパク質２リガンド、それを用いて調製される細胞、およびそれを使用する療法
US20230107927A1 (en) 2020-02-28 2023-04-06 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
CN114195806A (zh) * 2020-09-18 2022-03-18 上海医药集团股份有限公司 一种羰基杂环类化合物及其应用
US20240101552A1 (en) 2020-09-18 2024-03-28 Shanghai Pharmaceuticals Holding Co., Ltd. Carbonyl heterocyclic compound and application thereof
WO2022087146A1 (en) * 2020-10-22 2022-04-28 Landos Biopharma, Inc. Lancl ligands
CA3196954A1 (en) 2020-11-03 2022-05-12 Josep Bassaganya-Riera Crystalline forms of piperazine-1,4-diylbis((6-(1h-benzoi[d]imidazo-2-yl)pyridin-2yl)methanone) as lancl2 modulators
WO2022108997A2 (en) * 2020-11-19 2022-05-27 Landos Biopharma, Inc. Compounds, compositions, and methods for treating inflammatory or immune-mediated conditions of surface tissues
CN116670137A (zh) * 2020-12-15 2023-08-29 成都百裕制药股份有限公司 吡啶衍生物及其在医药上的应用
CN113908256B (zh) * 2021-11-26 2023-05-26 中国农业科学院兰州兽医研究所 Lancl1蛋白在制备抗病毒药物中的应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0282643A3 (en) 1986-11-22 1990-08-22 The Green Cross Corporation Use of pharmaceutical compositions comprising cyclohexane derivatives in the treatment or prevention of peptic ulcers
HUT78042A (hu) * 1994-12-23 1999-06-28 Smithkline Beecham Corporation 4,4-(diszubsztituált)-1-ciklohexanon-származékok, alkalmazásuk és a vegyületeket tartalmazó gyógyászati készítmények
US5856326A (en) 1995-03-29 1999-01-05 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
IL117580A0 (en) 1995-03-29 1996-07-23 Merck & Co Inc Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them
US5633388A (en) 1996-03-29 1997-05-27 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
US6297283B1 (en) * 1996-10-11 2001-10-02 Kowa Co., Ltd. Diamide compounds and compositions containing the same
CN1208333C (zh) * 1997-12-24 2005-06-29 Nikem研究有限公司 主要用于治疗骨质疏松的吲哚衍生物
WO1999038514A1 (en) 1998-02-02 1999-08-05 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
GB9914825D0 (en) * 1999-06-24 1999-08-25 Smithkline Beecham Spa Novel compounds
JP2001247550A (ja) * 1999-12-27 2001-09-11 Japan Tobacco Inc 縮合環化合物及びその医薬用途
CA2401489A1 (en) * 2000-03-02 2001-09-07 Ichiro Miki Oxygen-containing heterocyclic compounds
US20090124690A1 (en) 2000-04-03 2009-05-14 Alberte Randall S Generation of Combinatorial Synthetic Libraries and Screening for Novel Proadhesins and Nonadhesins
BR0113932A (pt) 2000-09-15 2003-06-24 Anormed Inc Compostos heterocìclicos que se ligam ao receptor da quimiocina
RU2297413C2 (ru) * 2000-09-15 2007-04-20 Анормед, Инк. Гетероциклические соединения, моделирующие активность хемокинового рецептора, их применение и содержащая их фармацевтическая композиция
SE0100902D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
AR040335A1 (es) 2002-06-26 2005-03-30 Glaxo Group Ltd Compuesto de ciclohexano o ciclohexeno, uso del mismo para preparar un medicamento, composicion farmaceutica que lo comprende, procedimiento y compuestos intermediarios de utilidad para preparar dicho compuesto
JPWO2005037269A1 (ja) 2003-10-21 2006-12-28 住友製薬株式会社 新規ピペリジン誘導体
JPWO2005082905A1 (ja) * 2004-02-26 2007-08-02 協和醗酵工業株式会社 二環性複素環化合物
US7674907B2 (en) 2004-07-23 2010-03-09 Amgen Inc. Furanopyridine derivatives and methods of use
EP1814393A4 (en) 2004-11-04 2010-02-03 Med College Georgia Res Inst TOLEROGENIC VACCINE AND METHOD THEREOF
WO2006053109A1 (en) 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Heteroaryl compounds
KR101099303B1 (ko) 2005-01-28 2011-12-26 주식회사 대웅제약 신규한 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
GB0508314D0 (en) * 2005-04-25 2005-06-01 Novartis Ag Organic compounds
CN100434419C (zh) 2005-06-03 2008-11-19 中国人民解放军军事医学科学院毒物药物研究所 单环多取代饱和环已酮类化合物及其制备方法和用途
US7754724B2 (en) 2005-06-30 2010-07-13 Dow Agrosciences Llc N-substituted piperazines
WO2007010964A1 (ja) 2005-07-22 2007-01-25 Shionogi & Co., Ltd. Ｐｇｄ２受容体アンタゴニスト活性を有するインドール誘導体
US7842692B2 (en) 2005-07-22 2010-11-30 Shionogi & Co., Ltd. Azaindole derivative having PGD2 receptor antagonistic activity
AU2006278397B2 (en) 2005-08-04 2013-01-17 Sirtris Pharmaceuticals, Inc. Oxazolopyridine derivatives as sirtuin modulators
EP1932839A4 (en) 2005-09-06 2014-09-10 Shionogi & Co INDOLECARBOXYLATE ACID DERIVATIVE HAVING ANTAGONIST EFFECT OF THE PGD2 RECEPTOR
ES2625378T3 (es) 2005-09-27 2017-07-19 Shionogi & Co., Ltd. Derivado de sulfonamida que tiene actividad antagonista del receptor de PGD2
UY29825A1 (es) 2005-10-03 2007-05-31 Astrazeneca Ab Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones
US20070203236A1 (en) 2006-01-11 2007-08-30 Smith Jeffrey W Novel antagonists of the human fatty acid synthase thioesterase
US8367727B2 (en) 2006-02-08 2013-02-05 Virginia Tech Intellectual Properties, Inc. Method of using abscisic acid to treat diseases and disorders
US7741367B2 (en) 2006-02-08 2010-06-22 Virginia Tech Intellectual Properties, Inc. Method of using abscisic acid to treat diseases and disorders
JP2008056615A (ja) 2006-08-31 2008-03-13 Fujifilm Corp ビニルエチニルアリールカルボン酸類、その製造方法及びそれを用いた熱架橋性化合物の製造方法
JP2010510254A (ja) 2006-11-24 2010-04-02 ワラタ ファーマシューティカルズ， インコーポレイテッド アルツハイマー病および関連の神経変性疾患のための併用処置
JP2010513519A (ja) 2006-12-22 2010-04-30 ミレニアム・ファーマシューティカルズ・インコーポレイテッド キナーゼインヒビター活性を有するある種のピラゾリン誘導体
US20090016990A1 (en) 2007-01-24 2009-01-15 Alberte Randall S Antimicrobial Compositions
MY146643A (en) 2007-07-30 2012-09-14 Dae Woong Pharma Novel benzoimidazole derivatives and pharmaceutical composition comprising the same
EP2628727A3 (en) 2007-11-21 2013-12-25 Decode Genetics EHF Biaryl PDE4 inhibitors for treating pulmonary and cardiovascular disorders
AU2008326381B2 (en) 2007-11-21 2014-10-23 Decode Genetics Ehf Biaryl PDE4 inhibitors for treating inflammation
WO2010050461A1 (ja) 2008-10-27 2010-05-06 田辺三菱製薬株式会社 新規アミド誘導体およびその医薬としての用途
EP2367824B1 (en) 2008-12-23 2016-03-23 AbbVie Inc. Anti-viral derivatives of pyrimidine
CA2647900C (en) 2008-12-23 2017-05-16 National Research Council Of Canada Inhibitors of a 9-cis-epoxycarotenoid dioxygenase
EP2367823A1 (en) 2008-12-23 2011-09-28 Abbott Laboratories Anti-viral compounds
CN102459227B (zh) 2009-04-17 2014-08-20 詹森药业有限公司 Ccr2的4-氮杂环丁烷基-1-苯基-环己烷拮抗剂
US9062564B2 (en) * 2009-07-31 2015-06-23 General Electric Company Solvent based slurry compositions for making environmental barrier coatings and environmental barrier coatings comprising the same
ES2749504T3 (es) * 2009-10-13 2020-03-20 Ligand Pharm Inc Compuestos de moléculas pequeñas miméticos del factor de crecimiento hematopoyético y sus usos
DE102009057167A1 (de) 2009-12-05 2011-06-09 Merck Patent Gmbh Elektronische Vorrichtung enthaltend Metallkomplexe
JP2011246461A (ja) 2010-04-27 2011-12-08 Mitsubishi Tanabe Pharma Corp 新規アミド誘導体を含有する医薬組成物
WO2011140215A2 (en) * 2010-05-04 2011-11-10 Virginia Tech Intellectual Properties, Inc. Lanthionine synthetase component c-like proteins as molecular targets for preventing and treating diseases and disorders
US8993624B2 (en) 2010-05-26 2015-03-31 Virginia Tech Intellectual Properties, Inc. Method of preventing and treating inflammatory diseases and disorders with abscisic acid
TW201211027A (en) 2010-06-09 2012-03-16 Janssen Pharmaceutica Nv Cyclohexyl-azetidinyl antagonists of CCR2
KR101743280B1 (ko) 2010-06-17 2017-06-02 얀센 파마슈티카 엔.브이. Ccr2의 사이클로헥실-아제티디닐 길항제
AU2011283684B2 (en) 2010-07-29 2015-08-27 Rigel Pharmaceuticals, Inc. AMPK-activating heterocyclic compounds and methods for using the same
KR20120035285A (ko) 2010-10-05 2012-04-16 에스케이이노베이션 주식회사 셀룰로오스아세테이트 필름
CA2861939A1 (en) 2011-12-30 2013-07-04 Centaurus Biopharma Co., Ltd. Novel arylalkene derivatives and use thereof as selective estrogen receptor modulators
CN103709115A (zh) 2012-10-09 2014-04-09 山东亨利医药科技有限责任公司 截短侧耳素类抗生素衍生物
RU2015134423A (ru) 2013-03-13 2017-04-26 Инфламматори Респонс Ресёрч, Инк. Применение левоцитиризина и монтелукаста при лечении аутоиммуных расстройств
US20150087673A1 (en) 2013-09-26 2015-03-26 Rigel Pharmaceuticals, Inc. Methods for using and biomarkers for ampk-activating compounds
JP6150701B2 (ja) 2013-09-30 2017-06-21 キヤノン株式会社 電子写真感光体、プロセスカートリッジおよび電子写真装置
PL3209655T3 (pl) * 2014-10-24 2020-12-28 Landos Biopharma, Inc. Leczenie oparte na białku 2 podobnym do syntetazy lantioniny C

Also Published As

Publication number Publication date
US20200046694A1 (en) 2020-02-13
PT3209655T (pt) 2020-11-13
RU2019110152A (ru) 2019-05-21
KR102026342B1 (ko) 2019-09-27
US10493072B2 (en) 2019-12-03
US20180055841A1 (en) 2018-03-01
AU2015337091B2 (en) 2018-11-22
JP2021073170A (ja) 2021-05-13
AU2021201405A1 (en) 2021-03-25
NZ732213A (en) 2019-02-22
AU2015337091A1 (en) 2017-06-15
NZ746737A (en) 2021-06-25
US11571419B2 (en) 2023-02-07
HUE051299T2 (hu) 2021-03-01
EP3757099B1 (en) 2022-06-01
US20160115153A1 (en) 2016-04-28
RU2017117562A3 (hr) 2018-11-26
US20170119762A1 (en) 2017-05-04
EP3209655A1 (en) 2017-08-30
US20200261447A1 (en) 2020-08-20
US10028950B2 (en) 2018-07-24
JP6806829B2 (ja) 2021-01-06
CA2965472C (en) 2021-08-24
US9556146B2 (en) 2017-01-31
IL275155A (en) 2020-07-30
SI3209655T1 (sl) 2020-11-30
ES2822987T3 (es) 2021-05-05
JP2017533263A (ja) 2017-11-09
RU2688677C2 (ru) 2019-05-22
US20180289703A1 (en) 2018-10-11
KR20170084115A (ko) 2017-07-19
JP6499306B2 (ja) 2019-04-10
CN107108573A (zh) 2017-08-29
PL3209655T3 (pl) 2020-12-28
DK3209655T3 (da) 2020-09-28
BR112017008416B1 (pt) 2023-05-09
WO2016064445A1 (en) 2016-04-28
CN111592508A (zh) 2020-08-28
LT3209655T (lt) 2021-01-11
US10849895B2 (en) 2020-12-01
IL252630A0 (en) 2017-07-31
RU2741576C2 (ru) 2021-01-27
RS61013B1 (sr) 2020-11-30
AU2021201405B2 (en) 2023-09-14
CN107108573B (zh) 2020-06-16
AU2019201231A1 (en) 2019-03-21
EP3209655B1 (en) 2020-07-15
US20210046070A1 (en) 2021-02-18
EP3757099A1 (en) 2020-12-30
IL275155B (en) 2021-04-29
RU2017117562A (ru) 2018-11-26
US20190125744A1 (en) 2019-05-02
JP2019142873A (ja) 2019-08-29
RU2019110152A3 (hr) 2019-09-26
US10201538B2 (en) 2019-02-12
IL252630B (en) 2020-06-30
KR20200087273A (ko) 2020-07-20
KR20190112181A (ko) 2019-10-02
CA2965472A1 (en) 2016-04-28
KR102134171B1 (ko) 2020-07-15
US20230142910A1 (en) 2023-05-11
RU2768888C1 (ru) 2022-03-25
US9839635B2 (en) 2017-12-12
US10682349B2 (en) 2020-06-16
BR112017008416A2 (pt) 2018-01-23

Similar Documents

Publication Publication Date Title
HRP20201416T1 (hr) Terapeutska sredstva na bazi sintetaze lantionin c-sličan 2
HRP20211300T1 (hr) Neuroaktivni steroidi
HRP20191579T1 (hr) Spojevi kao modulatori za ror gama
HRP20210693T1 (hr) Inhibitori beta-laktamaze
HRP20180791T1 (hr) Glioksamid supstituirani derivati pirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b
TR201908392T4 (tr) (6S,9aS)-N-benzil-6-((4-hidroksifenil)metil)-4,7-diokso-8-((6-(3-(piperazin-1-il)azetidin-1-il)piridin-2-il)metil)-2-(prop-2-en-1-il)-oktahidro-1h-pirazino(2,1-c)(1,2,4)triazin-1-karboksamid bileşiği.
HRP20210745T1 (hr) Supstituirani spojevi tetrahidrokinolinona kao ror gama modulatori
BR112015025716A2 (pt) pró-fármacos de nucleosídeo submetidos a deutério úteis para o tratamento de hcv
HRP20211429T1 (hr) Derivati sobetiroma
MY186898A (en) Condensed heterocyclic compounds and pesticides
PH12017502171A1 (en) PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
HRP20180081T1 (hr) Fuzionirani triciklični heterociklični spojevi kao inhibitori hiv integraze
BR112014031584A2 (pt) composto heterocíclico fundido
PH12015502232A1 (en) Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists
NZ716822A (en) Antiviral compounds
PH12016500147B1 (en) Plant disease control composition and its use
NZ712180A (en) Pyridazinone compounds and methods for the treatment of cystic fibrosis
MX2015014033A (es) Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
RS54708B1 (en) ARYLETINYL DERIVATIVES
RS53385B (en) DERIVATIVES OF HINAZOLIN-4 (3H) -ONE USED AS PI3 KINASE INHIBITOR
TR201911151T4 (tr) Jak2 ve alk2 inhibitörleri ve bunların kullanım yöntemleri.
HRP20201157T1 (hr) Triciklički heterocikli za liječenje raka
PH12017502408A1 (en) Bicyclic heterocyclic amide derivative
EA201792072A2 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
HRP20171273T1 (hr) Spoj dikarboksilne kiseline